Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group.

Cumulative incidences of second malignancies after 10 years were 10% (97.5% CI 7%–13%), 7% (4%–9%), and 7% (4%–10%) with 8xeBEACOPP, 6xeBEACOPP and 8xBEACOPP-14, respectively, suggesting a possible trend toward higher incidence in the standard arm (Fig. 6 A).

also in 1,410 other papers